Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Treatment

Some Groups Say Iowa HIV Transmission Law Worsens Stigma, Hinders Testing Efforts
Some Iowa groups are concerned that the state"s criminal HIV transmission law adds to the stigma associated with the virus and hampers testing efforts, and are urging lawmakers to revisit the law, the Iowa Independent reports. According to the Independent, criminal transmission of HIV is classified among the second-most serious felonies that can be committed in the state. Those that have been convicted under the law have been sentenced to a few months to several decades in prison. Former state Rep. Ed Fallon (D) who supported the 1998 law, said, "It seems to me that since it is now 11, almost 12, years later, it wouldn"t be [a] bad time to take a look at it again," adding that "surely [there] are some tweaks or changes that the legislature could consider relevant to this law, especially with all the new knowledge we have of the disease" (Waddington, 7/1).
generic viagra online
Cardiology Experts At Rush University Medical Center Successfully Use Unique Interventional Procedure To Save A Girl With A Very Rare Heart Defect
Seventeen-year-old Sara Abousuiony, who has been homebound since she was an infant, never imagined that she would be able to leave her home in Cairo, Egypt, and travel to the United States for a life-saving heart procedure.
News of the day
Nottingham University Selects Simplexo Enterprise For Five Year Clinical Trial, UK
Simplexo Enterprise, an enterprise search tool, has been selected by Nottingham University to enable the retrieval of information across a five-year clinical trial by its Division of Stroke Medicine into the causes and effects of strokes. The trial team is gathering and analysing information from more than 500 patients and several governing bodies in over 20 countries, including the UK, the United States, China, India and Australia.
Diagnostics

Promedior Initiates Phase 1 Clinical Trial Of PRM-151, A Novel Compound For The Treatment Of Fibrotic Diseases And Tissue Remodeling

Promedior, Inc. announced the initiation of a Phase 1 clinical trial of PRM-151, a novel compound in development for the treatment of fibrotic diseases and tissue remodeling. The Phase 1 dose escalation study is designed to evaluate the safety, tolerability, pharmacokinetics and exploratory pharmacodynamics of ascending single intravenous doses of PRM-151 in healthy subjects. The study is being conducted at the Centre for Human Drug Research in The Netherlands. PRM-151(rhSAP) is a recombinant form of human Serum Amyloid P, a highly conserved natural human protein that mediates its anti-fibrotic activity by targeting the specific cell populations that orchestrate fibrosis and tissue remodeling. PRM-151 has demonstrated an outstanding preclinical safety profile and robust preclinical efficacy by reducing fibrosis in multiple tissues, organs, and disease models. "The initiation of the Phase 1 clinical trial of PRM-151 represents an important milestone in the development of Promedior"s novel platform of products for the treatment of fibrotic diseases," said Dominick Colangelo, Chief Executive Officer of Promedior. "We believe that PRM-151 has tremendous potential to play an important role in improving patient outcomes across multiple disease indications and will position Promedior in a leadership position in the development of innovative anti-fibrotic therapeutics." "Through its fundamental role in regulating monocyte responses to injured tissue, we believe PRM-151 affects a common biology present in all forms of pathologic fibrosis," commented Dr. Mark Lupher, Jr., the company"s Senior Vice President of Discovery Research. "In collaboration with leading investigators at Harvard University, Yale University, University of Michigan, University of California San Diego and Rice University, we have consistently demonstrated significant anti-fibrotic activity across model systems, including in established disease settings, and are very excited to advance this novel compound into clinical research." Promedior, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009